Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 27;15:1469500. doi: 10.3389/fimmu.2024.1469500

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Boshart, Petrovic, Abovsky, Pastrello, Farkona, Manion, Neupane, Allen, Jurisica and Konvalinka

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

LGALS1 and its interactome expression in the kidney allografts with interstitial fibrosis and tubular atrophy (IFTA), from Venner et al., 2016 and Modena et al., 2016 (36, 37). (A) Heatmap showing 28 LGALS1 interactor genes differentially expressed in at least 3/4 comparisons to normally functioning kidney transplants or kidney transplants with mild/no IFTA (ci</=1). Red color indicates increased expression and blue color indicates decreased expression. LGALS1 is denoted by black arrow. (B) Top 15 pathways enriched (FDR: BH<0.01) among the concordant interactors from (A) (red). The size of the circle indicates the number of LGALS1 interactors in the pathway, and the color indicates significance. IFTA, interstitial fibrosis and tubular atrophy; IFTA ci>1, interstitial fibrosis and tubular atrophy with at least moderate interstitial fibrosis score; IFTA-I, interstitial fibrosis and tubular atrophy with inflammation; IFTA-NI, interstitial fibrosis and tubular atrophy with no inflammation; IFTA-AR, interstitial fibrosis and tubular atrophy with acute rejection.